CIK 0000730272
- Large accelerated filer
REPLIGEN CORP
Sign in to watch- Ticker
- RGEN
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 042729386
- Phone
- +1 781-449-9560
- Business address
- 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM, MA, 02453
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $4,976,580
- in 4 filings, $5.0M under 10b5-1 plans
Net −$4,976,580. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2019-09-19 | Hunt Anthony Chief Executive Officer | Sale | −452 | $83.72 | $38K | 219,413 |
| 2019-09-19 | Hunt Anthony Chief Executive Officer | Exercise or conversion · Stock Option (Right to Buy) | −20,000 | 18,127 | ||
| 2019-09-09 | Hunt Anthony Chief Executive Officer | Sale | −4,131 | $81.26 | $336K | 210,976 |
| 2019-09-09 | Hunt Anthony Chief Executive Officer | Sale | −4,926 | $82.15 | $405K | 206,050 |
| 2019-09-09 | Hunt Anthony Chief Executive Officer | Sale | −1,751 | $83.05 | $145K | 204,299 |
| 2019-09-09 | Hunt Anthony Chief Executive Officer | Sale | −740 | $84.64 | $63K | 203,559 |
| 2019-09-09 | Hunt Anthony Chief Executive Officer | Sale | −222 | $86.26 | $19K | 203,337 |
| 2019-09-09 | Hunt Anthony Chief Executive Officer | Sale | −288 | $89.27 | $26K | 203,049 |
| 2019-09-09 | Hunt Anthony Chief Executive Officer | Sale | −36 | $90.31 | $3K | 203,013 |
| 2019-07-15 | Snodgres Jon Chief Financial Officer | Shares withheld for taxes | −295 | $85.95 | $25K | 28,239 |
| 2019-06-17 | DAWES KAREN A Director | Exercise or conversion | +20,000 | $4.96 | $99K | 118,329 |
| 2019-06-17 | DAWES KAREN A Director | Sale | −1,295 | $77.35 | $100K | 117,034 |
| 2019-06-17 | DAWES KAREN A Director | Exercise or conversion · Stock Options (Right to Buy) | −20,000 | 0 | ||
| 2019-05-23 | COOPER GLENN L MD Director | Exercise or conversion | +24,000 | $5.00 | $120K | 64,709 |
| 2019-05-23 | COOPER GLENN L MD Director | Sale | −4,734 | $66.91 | $317K | 59,975 |
| 2019-05-23 | COOPER GLENN L MD Director | Sale | −266 | $67.53 | $18K | 59,709 |
| 2019-05-23 | COOPER GLENN L MD Director | Exercise or conversion · Stock Option (Right to Buy) | −24,000 | 0 | ||
| 2019-05-23 | COOPER GLENN L MD Director | Sale | −4,734 | $66.91 | $317K | 35,975 |
| 2019-05-23 | COOPER GLENN L MD Director | Sale | −266 | $67.53 | $18K | 35,709 |
| 2019-05-15 | RYAN THOMAS F JR Director | Grant or award | +923 | 4,148 |
Page 41 of 42 · 832 trades